Plate VI.
Cabinet of questions
The recurring confusions a careful reader runs into, answered against the trial record.
What is tirzepatide and how does it differ from selective GLP-1 receptor agonists?
Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptors at once: the GIP receptor and the GLP-1 receptor. Selective GLP-1 receptor agonists — the class that includes semaglutide, dulaglutide, and liraglutide — activate the GLP-1 receptor only. The dual mechanism appears to produce greater reductions in HbA1c and body weight than selective GLP-1 receptor activation alone, both in preclinical models [4] and in head-to-head clinical trials [6][11]. The dual agonist also shows a distinctive signaling profile at the GLP-1 receptor — biased toward cAMP signaling over beta-arrestin recruitment — which reduces receptor internalization and may contribute to sustained receptor availability across the once-weekly dosing window [2].
How does the dual GIP and GLP-1 receptor agonism work mechanistically?
A single peptide backbone engages both receptors, but not symmetrically. Tirzepatide's affinity for the GIP receptor is comparable to native GIP, while its affinity for the GLP-1 receptor is approximately 18- to 20-fold weaker than native GLP-1 [2]. The molecule is therefore an imbalanced dual agonist. Cryo-electron-microscopy structures of tirzepatide bound to each receptor have resolved the molecular basis: the shared peptide N-terminus engages both receptors but with distinct conformational dynamics [3]. Downstream, the combined receptor activity produces glucose-dependent insulin secretion, central appetite suppression, transient gastric emptying delay, and effects on adipose tissue and hepatic glucose output.
What does the SURMOUNT clinical trial program show about tirzepatide and weight reduction?
SURMOUNT-1 (n=2,539) reported mean weight reductions of 15.0, 19.5, and 20.9 percent over 72 weeks at the 5, 10, and 15 mg weekly doses, against 3.1 percent on placebo, in adults with obesity or overweight without diabetes [8]. Between 85 and 91 percent of tirzepatide-treated participants achieved at least 5 percent weight loss, and approximately 57 percent of the 15 mg arm achieved at least 20 percent. A body-composition substudy reported that the weight lost was approximately three-to-one fat mass to lean mass [9]. SURMOUNT-4 demonstrated that continued therapy supports durable maintenance, with substantial regain following randomized withdrawal [10]. SURMOUNT-5 showed greater weight reduction with tirzepatide than with semaglutide in a head-to-head obesity trial [11].
What does the SURPASS program show about glycemic control in type 2 diabetes?
Across SURPASS 1 through 5, tirzepatide produced HbA1c reductions of −1.9 to −2.6 percentage points and body-weight reductions of 6.6 to 13.9 percent over 40 to 52 weeks, with up to 92 percent of participants reaching HbA1c below 7 percent [17]. SURPASS-2 against semaglutide 1 mg reported HbA1c reductions of −2.01, −2.24, and −2.30 percentage points at the three tirzepatide doses against −1.86 for semaglutide, with greater weight reduction across all three arms [6]. SURPASS-4 demonstrated lower hypoglycemia rates with tirzepatide than with titrated insulin glargine (6–9 percent vs 19 percent) and a reduction in the composite renal endpoint of approximately 41 percent [7].
What is the plasma half-life of tirzepatide and why does it support once-weekly dosing?
The elimination half-life of tirzepatide in humans is approximately five days. The figure derives from the molecule's albumin-tethering design: a C20 fatty di-acid moiety on the backbone drives approximately 99 percent plasma albumin binding, which extends plasma residence time substantially compared with the native incretin peptides [1]. Absolute bioavailability following subcutaneous administration is approximately 80 percent and mean apparent clearance is 0.061 L/h. Steady-state plasma concentration is reached after approximately four weeks of weekly dosing — the basis for the four-week minimum interval between titration steps in both the trial protocols and the FDA-labeled regimen.
What does recent research say about obstructive sleep apnea, MASH, and heart failure?
SURMOUNT-OSA (n=469) reported that 10 or 15 mg weekly tirzepatide reduced the apnea-hypopnea index by approximately 25 to 29 events per hour over 52 weeks in adults with moderate-to-severe obstructive sleep apnea and obesity, both with and without concurrent positive airway pressure therapy [12]. SYNERGY-NASH (n=190, Phase 2) reported that 73.3 percent of participants on 15 mg achieved resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis at 52 weeks, against 13.2 percent on placebo [14]. SUMMIT (n=731) reported a 38 percent reduction in the composite of cardiovascular death or worsening heart failure events in patients with heart failure with preserved ejection fraction and obesity, with concurrent improvements in NT-proBNP, six-minute walk distance, and KCCQ-CSS [13].
How do tirzepatide's effects compare with semaglutide in head-to-head studies?
Two head-to-head trials inform the comparison. SURPASS-2 (n=1,879, 40 weeks, type 2 diabetes) reported greater HbA1c and body-weight reductions with all three tirzepatide doses than with semaglutide 1 mg [6]. SURMOUNT-5 (n=751, 72 weeks, obesity without diabetes) reported a mean weight reduction of 20.2 percent on tirzepatide against 13.7 percent on semaglutide, a waist-circumference change of −18.4 cm against −13.0 cm, and at least 30 percent weight loss in 19.7 percent of tirzepatide-treated participants against 6.9 percent on semaglutide [11]. A real-world cohort study of patients with MASLD/MASH, obesity, and type 2 diabetes reported favorable cardiovascular outcomes and lower acute kidney injury incidence with tirzepatide than with semaglutide in comparable cohorts [20].
What are the known adverse-event risks identified in tirzepatide clinical trials?
The most common adverse events across the trial program were gastrointestinal: nausea, vomiting, diarrhea, and constipation, predominantly during dose escalation. Per the FDA label, acute pancreatitis was reported at 0.23 per 100 patient-years in tirzepatide-treated participants against 0.11 per 100 patient-years in comparators [18]. Acute gallbladder disease (cholelithiasis, biliary colic, cholecystectomy) was reported at 0.1 to 1 percent incidence, with risk appearing to scale with rapid weight loss. The labeled product carries a boxed warning concerning thyroid C-cell tumors based on a rodent signal of dose- and duration-dependent C-cell tumors; the labeled product is contraindicated in patients with personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 [18]. Lean-mass loss accounted for approximately 11 percent of the weight lost in the SURMOUNT-1 body-composition analysis [9].
What background therapies has tirzepatide been studied with?
Metformin was the most common background therapy across the SURPASS program, including SURPASS-2 [6]. Pooled SURPASS analyses preserved the renal and glycemic effects irrespective of background SGLT2 inhibitor or RAS inhibitor use [16]. SURPASS-5 examined tirzepatide added to titrated basal insulin, with the combination producing greater HbA1c reduction with less weight gain than insulin intensification alone. The mechanisms of metformin (hepatic glucose output reduction) and the incretin pathway (insulin secretion and appetite) are non-overlapping, which is the proposed reason for the additive effect across these combinations.
What is the cardiovascular outcomes evidence base for tirzepatide?
SURPASS-CVOT (n≈13,000) is the first head-to-head cardiovascular outcomes trial between two incretin therapies. Adults with type 2 diabetes and established atherosclerotic cardiovascular disease were randomized to tirzepatide or dulaglutide 1.5 mg weekly. Over a median four-year follow-up, the primary three-component MACE event rate was 12.2 percent on tirzepatide against 13.1 percent on dulaglutide (HR 0.92, 95.3% CI 0.83–1.01), meeting non-inferiority. All-cause mortality was 16 percent lower on tirzepatide (HR 0.84, 95.0% CI 0.75–0.94) [15]. SURPASS-4 had earlier demonstrated non-inferior cardiovascular safety against titrated insulin glargine in a high-risk type 2 diabetes population, with no excess in adjudicated MACE-4 events [7].
Is tirzepatide a peptide that I can buy from a research-chemical supplier?
Tirzepatide is an FDA-approved prescription medicine in the United States. Material sold as 'tirzepatide' outside the regulated pharmaceutical supply chain is intended for laboratory research only and is not characterized for human use. Identity, purity, sterility, and endotoxin content of such products are not verified by any regulatory authority. Questions about the approved formulation are appropriately addressed to a licensed prescribing clinician.
How is body composition affected — is it just fat loss?
A body-composition substudy of SURMOUNT-1 reported that the weight lost on tirzepatide was approximately three-to-one fat mass to lean mass — a 33.9 percent reduction in fat mass against a 10.9 percent reduction in lean mass — with concurrent reductions in both visceral and subcutaneous adipose tissue [9]. The ratio is more favorable than would be expected for an equivalent magnitude of weight loss from caloric restriction alone in many populations, although direct comparisons are not available within the trial. The long-term implications of the lean-mass component, particularly in older adults at risk for sarcopenia, remain under study.
What happens after stopping tirzepatide?
SURMOUNT-4 (n=670) addressed this directly. Participants were openly treated to a maximum tolerated dose (10 or 15 mg weekly) and then randomized to continued tirzepatide or placebo through week 88. The continued-therapy arm maintained 80 percent or more of initial weight loss in 89.5 percent of participants, with mean total weight reduction of 25.3 percent. Randomized withdrawal to placebo led to substantial weight regain, with mean total weight reduction at week 88 of 9.9 percent against 25.3 percent for continued therapy [10]. The trial supports framing of tirzepatide as chronic therapy when used for weight management.
Does the FDA label name the brands that this site refuses to name?
Yes — the FDA label names the proprietary brand of the approved tirzepatide injection. This site refers to the compound by its International Nonproprietary Name only, which is the editorial convention adopted across all pages and which is consistent with the practice of independent scholarly and pharmacopoeial publications. Readers interested in the brand-named product should consult the official FDA label [18] or speak with a licensed prescribing clinician.